Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
04 août 2022 09h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
03 août 2022 16h00 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
20 mai 2021 16h05 HE
|
Processa Pharmaceuticals, Inc.
~Processa’s trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica. Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562.~ HANOVER, MD., May 20,...
PROCESSA PHARMACEUTICALS ANNOUNCES RESULTS FROM THE PHASE 2 STUDY IN NECROBIOSIS LIPOIDICA
17 mars 2020 09h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 17, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499
15 juil. 2019 09h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, July 15, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
PROCESSA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA
29 janv. 2019 09h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
PROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY
09 janv. 2019 09h00 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...